Different Glycosylation Pattern of Human IgG1 and IgG3 Antibodies Isolated from Transiently as well as Permanently Transfected Cell Lines

Scandinavian Journal of Immunology

Volumn 77, Issue 5, 2013, Pages 419-428

  Vestrheim, A C ^a,b   Moen, A ^b   Egge Jacobsen, W ^b   Bratlie, D B ^a   Michaelsen, T E ^a,b  

^a NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C1Q; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G3 ANTIBODY;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; BINDING SITE; CELL LINE; CELL STRAIN HEK293; COMPLEMENT ACTIVATION; GENETIC TRANSFECTION; GLYCOSYLATION; HUMAN; HUMAN CELL; POINT MUTATION; PRIORITY JOURNAL; PROTEIN STRUCTURE; SUPERNATANT; WILD TYPE;

ANIMALS; ANTIBODIES; BINDING SITES; CELL LINE, TUMOR; FUCOSE; GLYCOPROTEINS; GLYCOSYLATION; HEK293 CELLS; HUMANS; IMMUNOGLOBULIN G; MASS SPECTROMETRY; MUTATION; RECOMBINANT PROTEINS; TIME FACTORS; TRANSFECTION;

EID: 84876803338     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/sji.12046     Document Type: Article

References (49)

1. Kaneko Y, Nimmerjahn F, Ravetch JV. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 2006;313:670-3.
2. Nimmerjahn F, Ravetch JV. Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science 2005;310:1510-2.
3. Loizou S, Cofiner C, Weetman AP, Walport MJ. Immunoglobulin class and IgG subclass distribution of anticardiolipin antibodies in patients with systemic lupus erythematosus and associated disorders. Clin Exp Immunol 1992;90:434-9.
4. Jefferis R, Pound J, Lund J, Goodall M. Effector mechanisms activated by human IgG subclass antibodies: clinical and molecular aspects. Review article. Ann Biol Clin (Paris) 1994;52:57-65.
5. Ishizaka ST, Piacente P, Silva J, Mishkin EM. IgG subtype is correlated with efficiency of passive protection and effector function of anti-herpes simplex virus glycoprotein D monoclonal antibodies. J Infect Dis 1995;172:1108-11.
6. Jefferis R. Antibody therapeutics: isotype and glycoform selection. Expert Opin Biol Ther 2007;7:1401-13.
7. Burton DR, Woof JM. Human Antibody Effector Function. In: Frank JD, ed. Advances in Immunology. Volume 51 ed. San Diego, CA: Academic Press, 1992: 1-84.
8. Garred P, Michaelsen TE, Aase A. The IgG subclass pattern of complement activation depends on epitope density and antibody and complement concentration. Scand J Immunol 1989;30:379-82.
9. Michaelsen TE, Garred P, Aase A. Human IgG subclass pattern of inducing complement-mediated cytolysis depends on antigen concentration and to a lesser extent on epitope patchiness, antibody affinity and complement concentration. Eur J Immunol 1991;21:11-6.
10. Lis H, Sharon N. Protein glycosylation. Structural and functional aspects. Eur J Biochem 1993;218:1-27.
11. Varki A. Biological roles of oligosaccharides: all of the theories are correct. Glycobiology 1993;3:97-130.
12. Jefferis R. Isotype and glycoform selection for antibody therapeutics. Arch Biochem Biophys 2012;526:159-66.
13. Chames P, Van RM, Weiss E, Baty D. Therapeutic antibodies: successes, limitations and hopes for the future. Br J Pharmacol 2009;157:220-33.
14. Beckman RA, Weiner LM, Davis HM. Antibody constructs in cancer therapy: protein engineering strategies to improve exposure in solid tumors. Cancer 2007;109:170-9.
15. Cartron G, Dacheux L, Salles G et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002;99:754-8.
16. Beck A, Wagner-Rousset E, Ayoub D, Van DA, Sanglier-Cianferani S. Characterization of therapeutic antibodies and related products. Anal Chem 2013;85:715-36.
17. Beck A, Wurch T, Bailly C, Corvaia N. Strategies and challenges for the next generation of therapeutic antibodies. Nat Rev Immunol 2010;10:345-52.
18. Reichert JM. Which are the antibodies to watch in 2012? MAbs 2012;4:1-3.
19. Reichert JM. Marketed therapeutic antibodies compendium. MAbs 2012;4:413-5.
20. Tao MH, Morrison SL. Studies of aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region. J Immunol 1989;143:2595-601.
21. Mimura Y, Sondermann P, Ghirlando R et al. Role of oligosaccharide residues of IgG1-Fc in Fc gamma RIIb binding. J Biol Chem 2001;276:45539-47.
22. Tsuchiya N, Endo T, Matsuta K et al. Effects of galactose depletion from oligosaccharide chains on immunological activities of human IgG. J Rheumatol 1989;16:285-90.
23. Matsumoto A, Shikata K, Takeuchi F, Kojima N, Mizuochi T. Autoantibody activity of IgG rheumatoid factor increases with decreasing levels of galactosylation and sialylation. J Biochem 2000;128:621-8.
24. Wuhrer M, Stam JC, van de Geijn FE et al. Glycosylation profiling of immunoglobulin G (IgG) subclasses from human serum. Proteomics 2007;7:4070-81.
25. Rook GA, Steele J, Brealey R et al. Changes in IgG glycoform levels are associated with remission of arthritis during pregnancy. J Autoimmun 1991;4:779-94.
26. Shields RL, Lai J, Keck R et al. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J Biol Chem 2002;277:26733-40.
27. Nimmerjahn F, Ravetch JV. The antiinflammatory activity of IgG: the intravenous IgG paradox. J Exp Med 2007;204:11-5.
28. Bruhns P, Samuelsson A, Pollard JW, Ravetch JV. Colony-Stimulating Factor-1-Dependent Macrophages Are Responsible for IVIG Protection in Antibody-Induced Autoimmune Disease. Immunity 2003;18:573-81.
29. Jefferis R. Glycosylation as a strategy to improve antibody-based therapeutics. Nat Rev Drug Discov 2009;8:226-34.
30. Coloma MJ, Clift A, Wims L, Morrison SL. The role of carbohydrate in the assembly and function of polymeric IgG. Mol Immunol 2000;37:1081-90.
31. Nallet S, Fornelli L, Schmitt S et al. Glycan variability on a recombinant IgG antibody transiently produced in HEK-293E cells. New Biotechnol 2012;29:471-6.
32. Shaw G, Morse S, Ararat M, Graham FL. Preferential transformation of human neuronal cells by human adenoviruses and the origin of HEK 293 cells. FASEB J 2002;16:869-71.
33. Oi VT, Morrison SL, Herzenberg LA, Berg P. Immunoglobulin gene expression in transformed lymphoid cells. Proc Natl Acad Sci USA 1983;80:825-9.
34. Lasunskaia EB, Fridlianskaia II, Darieva ZA, da Silva MS, Kanashiro MM, Margulis BA. Transfection of NS0 myeloma fusion partner cells with HSP70 gene results in higher hybridoma yield by improving cellular resistance to apoptosis. Biotechnol Bioeng 2003;81:496-504.
35. Selman MH, Derks RJ, Bondt A et al. Fc specific IgG glycosylation profiling by robust nano-reverse phase HPLC-MS using a sheath-flow ESI sprayer interface. J Proteomics 2012;75:1318-29.
36. Gorfien S, Paul B, Walowitz J, Keem R, Biddle W, Jayme D. Growth of NS0 cells in protein-free, chemically defined medium. Biotechnol Prog 2000;16:682-7.
37. Lund J, Takahashi N, Nakagawa H et al. Control of IgG/Fc glycosylation: a comparison of oligosaccharides from chimeric human/mouse and mouse subclass immunoglobulin Gs. Mol Immunol 1993;30:741-8.
38. Lund J, Takahashi N, Pound JD, Goodall M, Jefferis R. Multiple interactions of IgG with its core oligosaccharide can modulate recognition by complement and human Fc gamma receptor I and influence the synthesis of its oligosaccharide chains. J Immunol 1996;157:4963-9.
39. Michaelsen TE, Sandlie I, Bratlie DB, Sandin RH, Ihle O. Structural difference in the complement activation site of human IgG1 and IgG3. Scand J Immunol 2009;70:553-64.
40. Aase A, Michaelsen TE. The use of a hapten-Fab conjugate to sensitize target cells for antibody-dependent complement-mediated lysis and antibody-dependent cell-mediated cytotoxicity. J Immunol Methods 1991;136:185-91.
41. Michaelsen TE, Frangione B, Franklin EC. Primary structure of the "hinge" region of human IgG3. Probable quadruplication of a 15-amino acid residue basic unit. J Biol Chem 1977;252:883-9.
42. Huck S, Fort P, Crawford DH, Lefranc MP, Lefranc G. Sequence of a human immunoglobulin gamma 3 heavy chain constant region gene: comparison with the other human C gamma genes. Nucleic Acids Res 1986;14:1779-89.
43. Michaelsen TE, Aase A, Westby C, Sandlie I. Enhancement of complement activation and cytolysis of human IgG3 by deletion of hinge exons. Scand J Immunol 1990;32:517-28.
44. Reid CQ, Tait A, Baldascini H et al. Rapid whole monoclonal antibody analysis by mass spectrometry: an ultra scale-down study of the effect of harvesting by centrifugation on the post-translational modification profile. Biotechnol Bioeng 2010;107:85-95.
45. Lund J, Takahashi N, Hindley S, Tyler R, Goodall M, Jefferis R. Glycosylation of human IgG subclass and mouse IgG2b heavy chains secreted by mouse J558L transfectoma cell lines as chimeric antibodies. Hum Antibodies Hybridomas 1993;4:20-5.
46. Croset A, Delafosse L, Gaudry JP et al. Differences in the glycosylation of recombinant proteins expressed in HEK and CHO cells. J Biotechnol 2012;161:336-48.
47. Ashwell G, Harford J. Carbohydrate-specific receptors of the liver. Annu Rev Biochem 1982;51:531-54.
48. Lifely MR, Hale C, Boyce S, Keen MJ, Phillips J. Glycosylation and biological activity of CAMPATH-1H expressed in different cell lines and grown under different culture conditions. Glycobiology 1995;5:813-22.
49. Michaelsen TE, Aase A, Norderhaug L, Sandlie I. Antibody dependent cell-mediated cytotoxicity induced by chimeric mouse-human IgG subclasses and IgG3 antibodies with altered hinge region. Mol Immunol 1992;29:319-26.